REL proto-oncogene (c-Rel) (C-Term) Peptide
c-Rel
Reactivity: Human, Mouse
Host: Synthetic
BP, WB
Catalog No. ABIN2185648
Quick Overview for REL proto-oncogene (c-Rel) (C-Term) Peptide (ABIN2185648)
Target
c-Rel
(REL proto-oncogene (c-Rel))
Origin
Human, Mouse
Source
Synthetic
Application
Blocking Peptide (BP), Western Blotting (WB)
-
-
Protein Region
- C-Term
-
Sequence
- FSCVDNGLMN EPGLSDDANN PTFVQSSHYS VNTLQSEQLS DPFTYGFFKI
-
Characteristics
- This is a synthetic peptide designed for use in combination with anti-Rel Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
Purification
- Purified
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Concentration
- 1 mg/mL
-
Buffer
- Final peptide concentration is 1 mg/mL in PBS.
-
Handling Advice
- Avoid repeat freeze-thaw cycles.
-
Storage
- -20 °C
-
Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- c-Rel (REL proto-oncogene (c-Rel))
-
Background
-
Proto-oncogene that may play a role in differentiation and lymphopoiesis. NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. The NF-kappa-B heterodimer RELA/p65-c-Rel is a transcriptional activator.
Protein Size: 587 -
Molecular Weight
- 64 kDa
-
UniProt
- P15307
Target
-
You are here:
